Demonstrated efficacy and safety in older patients, night after night

Rozerem did not impair balance or memory in older adults.

Ramelteon, marketed as Rozerem by Takeda Pharmaceuticals North America, is the first in a new class of sleep agents that selectively binds to the MT1 and MT2 receptors in the suprachiasmatic nucleus (SCN), versus binding to GABA A receptors, such as with drugs like zolpidem, eszopiclone, and zaleplon. Ramelteon is approved by the U.S. Food and Drug Administration (FDA) for long-term use.

Ramelteon does not show any appreciable binding to GABAA receptors, which are associated with anxiolytic, myorelaxant, and amnesic effects.

Ramelteon is used for insomnia, particularly delayed sleep onset. Ramelteon has not been shown to produce dependence and has shown no potential for abuse, and the withdrawal and rebound insomnia that is typical with other GABA modulators is not present in ramelteon. It is currently the only non-scheduled prescription drug for the treatment of insomnia available in the United States. Some clinicians also use ramelteon for the treatment of Delayed sleep phase disorder.

More on Wikipedia

From Wikipedia (text available under Creative Commons Attribution/Share-Alike License)

Brand name: Rozerem
Generic name/category: Ramelteon, Sedatives, Indanes
Company: Takeda Pharmaceuticals North America
Country/Market: USA, North America
Indication(s)/use: insomnia, difficulty with sleep onset
Target: Healthcare Professionals (HCP)
Medium: Print ad
Size/duration double-page spread
Publication/Aired: Pharmacy And Therapeutics – February 2008

To see all of this brand's ads on AdPharm, click here
0 views
Aug 25, 2009

Click on image to view the banner on AdPharm

Tired of morning coming in the middle of the night?

Silence your rooster with Ambien CR, so you can wake up less frequently and fall back asleep faster.

Get your 7-night free trial offer [inactive link]

Brand name: Ambien CR
Generic name/category: Zolpidem, Anxiolytics, Hypnotics, Imidazopyridines, Sedatives
Company: Sanofi-Aventis
Country/Market: USA, North America
Indication(s)/use: short-term treatment of insomnia
Target: Consumers (DTC)
Publication: 2009

To see all of this brand’s ads on AdPharm, click here